Merck & Co. MRK · NYSE
$145.27 -1.34% (-$1.97)
Summary
42 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 15 years in a row.
- Out of every 100 USD of revenue, 24 USD is left as free cash.
What to watch
- It pays out more in dividends than it earns: 264% of profit.
- Revenue growth is slowing: 3.1% a year over the last 3 years against 9.4% over 5 years.
- It earns only 5.6 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 114.5 USD for 1 USD of yearly profit. Over the last five years it was 164.9 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.4% a year over 5 years. Over the last 3 years it grew by 3.1% a year. For the next fiscal year analysts expect revenue to grow by 3.3%. Earnings per share grew by 8.4% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 25 USD
- Research and development 43 USD
- Sales and administration 16 USD
- Taxes and other 12 USD
- Net profit 4.8 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 4.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.31%
- Paid out of profit
- 264%
- Raised in a row
- 15 years
You receive $3.40 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 26
- Hold 11
- Sell 1
Today's price within the analysts' price targets
The average target of $158.22 is 8.9% above today's price. 68% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Pharmaceutical segment 89%
- Animal Health segment 9.8%
- Other Segments 0.8%
By region
- UNITED STATES 56%
- EMEA 22%
- Latin America 5.2%
- Asia Pacific 4.6%
- International 4.4%
- Other 7.2%
Pharmaceutical segment brings in 89% of revenue.
Segments in detail